Back to User profile » Dr Jinghui Lin

Papers published by Dr Jinghui Lin:

Clinical Trial Report

Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial

Lin J, Li M, Chen S, Weng L, He Z

Journal of Inflammation Research 2021, 14:2557-2567

Published Date: 16 June 2021

Corrigendum

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]

Wang Q, Liao J, He Z, Su Y, Lin D, Xu L, Xu H, Lin J

OncoTargets and Therapy 2021, 14:2337-2338

Published Date: 6 April 2021

Corrigendum

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]

Wang Q, Liao J, He Z, Su Y, Lin D, Xu L, Xu H, Lin J

OncoTargets and Therapy 2021, 14:253-254

Published Date: 12 January 2021

Original Research

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling

Wang Q, Liao J, He Z, Su Y, Lin D, Xu L, Xu H, Lin J

OncoTargets and Therapy 2020, 13:10983-10994

Published Date: 28 October 2020

Original Research

Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study

He ZY, Li MF, Lin JH, Lin D, Lin RJ

Cancer Management and Research 2019, 11:2129-2138

Published Date: 14 March 2019